The promise of genome editing to help understand human diseases and create new therapies is vast, but technological ...

A new study from the Norwegian Institute of Food, Fisheries, and Aquaculture Research (Nofima) has analyzed different salmon ...

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

Scientific breakthroughs have had life-changing effects on our nation's health and economy. Now is not the time to slash ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

Editas Medicine ( EDIT 12.04%) is a promising clinical-stage company that has captured Wall Street's attention at the ...